Nicaise Claude 4

What Happened
Claude Nicaise, a director of Sarepta Therapeutics (SRPT), exercised stock options on 2026-01-29 to acquire 10,500 shares at an exercise price of $13.71 per share (total value of exercised shares = $143,955). To cover the exercise price/tax liability, 6,780 shares were withheld/disposed at $21.23 per share (value = $143,939). The filing also shows the conversion/termination of the underlying derivative instrument (10,500 units) related to the exercise (reported with $0 consideration).

Key Details

• Transaction date: 2026-01-29.
• Option exercise (Code M): 10,500 shares acquired @ $13.71 = $143,955.
• Withholding to cover exercise/taxes (Code F): 6,780 shares disposed @ $21.23 = $143,939. Footnote F1: shares were withheld by the issuer to satisfy payment; the reporting person retains the exercised shares not withheld.
• Derivative conversion (Code M): 10,500 units reported disposed @ $0 — reflects termination/conversion of the options upon exercise.
• Filing timeliness: Reported on 2026-01-29 (no late filing indicated).
• Shares owned after the transaction: not specified in the summary information provided; see the full Form 4 for current holdings.

Context

• This was an option exercise with partial cashless settlement: some of the newly acquired shares were withheld by the company to cover the exercise price/taxes rather than the insider paying cash.
• Option exercises that result in withholding are common and are administrative/compensatory actions; they do not necessarily indicate a buy/sell market sentiment by themselves.